Specific immunotherapy in asthma: Efficacy and safety

Clinical and Experimental Allergy

Volumn 41, Issue 9, 2011, Pages 1247-1255

  Passalacqua, G ^a   Canonica, G W ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALTERNARIA ALLERGEN; ANTIHISTAMINIC AGENT; BIRCH ALLERGEN; BRONCHODILATING AGENT; BUDESONIDE; CAT ALLERGEN; DOG ALLERGEN; FLUTICASONE; GRASS POLLEN ALLERGEN; HOUSE DUST ALLERGEN; MITE ALLERGEN; MONTELUKAST; OLIVE ALLERGEN; PARIETARIA ALLERGEN; PHL P 5 ALLERGEN; PLACEBO; POLLEN ANTIGEN; RAGWEED ANTIGEN; STEROID; UNCLASSIFIED DRUG;

ADD ON THERAPY; ASTHMA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HAY FEVER; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG FUNCTION; META ANALYSIS (TOPIC); MOUTH PRURITUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RISK FACTOR; SPECIFIC IMMUNOTHERAPY; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; THROAT IRRITATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, SUBLINGUAL; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; TREATMENT OUTCOME;

EID: 80051797386     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2010.03688.x     Document Type: Review

References (86)

1. Bousquet J, Lockey RF, Malling HJ(eds). Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998; 54(Suppl 82):1-33.
2. Bonifazi F, Bilò MB. Efficacy of specific immunotherapy in allergic asthma: myth or reality? Allergy 1997; 52:698-710.
3. Cox L. Allergen immunotherapy and asthma: efficacy, safety, and other considerations. Allergy Asthma Proc 2008; 29:580-9.
4. Nelson HS. Allergen immunotherapy: where is it now? J Allergy Clin Immunol 2007; 119:769-79.
5. Saltoun CA. Update on efficacy of allergen immunotherapy for allergic rhinitis and asthma. Allergy Asthma Proc 2002; 23:377-80.
6. Bousquet J, Demoly P, Michel FB. Specific immunotherapy in rhinitis and asthma. Ann Allergy Asthma Immunol 2001; 87 (1 Suppl 1):38-42.
7. Creticos PS. The consideration of immunotherapy in the treatment of allergic asthma. J Allergy Clin Immunol 2000; 105:S559-74.
8. Cruz AA, Popov T, Pawankar R et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007; 62 (Suppl 84):1-41.
9. Bousquet PJ, Brozek J, Bachert C et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 2009; 64:1737-45.
10. Canonica GW, Baena Cagnani C, Bousquet J et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-24.
11. Hedlin G, Wille S, Browaldh L et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999; 103:609-14.
12. Paranos S, Petrovic S. Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics. J Investig Allergol Clin Immunol 7:588-95.
13. Adkinson NF, Eggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336:324-31.
14. Bødtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002; 57:297-305.
15. Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162:2048-52.
16. Arvidsson MB, Löwhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109:777-83.
17. González P, Florido F, Sáenz de San Pedro B, de la Torre F, Rico P, Martín S. Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment. J Investig Allergol Clin Immunol 2002; 12:263-71.
18. Basomba A, Tabar AI, de Rojas DH et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 2002; 109:943-8.
19. Guerra F, Daza JC, Almeda E. Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens. Significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment. J Investig Allergol Clin Immunol 2003; 13:108-17.
20. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003; 33:1076-82.
21. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Regione Veneto Study Group on the "Effect of immunotherapy in allergic asthma". Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004; 113:643-9.
22. Arvidsson MB, Löwhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy 2004; 59:74-80.
23. Ferrer A, García-Sellés J. Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae. J Investig Allergol Clin Immunol 2003; 13:244-51.
24. Mirone C, Albert F, Tosi A et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34:1408-14.
25. Ameal A, Vega-Chicote JM, Fernández S et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005; 60:1178-83.
26. Wang H, Lin X, Hao C et al. Double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006; 61:191-7.
27. Ferrer M, Burches E, Peláez A et al. Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance. J Investig Allergol Clin Immunol 2005; 15:283-92.
28. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117:263-8.
29. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006; 61:843-8.
30. García-Robaina JC, Sánchez I, de la Torre F, Fernández-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006; 118:1026-32.
31. Tabar AI, Lizaso MT, García BE et al. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Pediatr Allergy Immunol 2008; 19:67-75.
32. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151:969-74.
33. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; 4:CD001186.
34. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; 8:CD001186.
35. Shaaban R, Zureik M, Soussan D et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372:1049-57.
36. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children - a 14-year study. Pediatrics 1968; 42:793-802.
37. Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
38. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-8.
39. Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108:921-8.
40. Shaikh WA. Immunotherapy vs inhaled budesonide in bronchial asthma: an open, parallel, comparative trial. Clin Exp Allergy 1997; 27:1279-84.
41. Cox L, Larenas Linneman D, Lockey RF, Passalacqua G. Speaking a common language in immunotherapy. WAO grading of systemic reactions. J Allergy Clin Immunol 2010; 125:569-74.
42. Lockey RF, Benedicts LM, Turkeltaub PC, Platt-Mills TA. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987; 76:660-77.
43. Reid MJ, Lockey RF, Turkeltaub PC, Platt-Mills TA. Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993; 92:6-15.
44. Bernstein DI, Wanner M, Borish L, Liss GM. Immunotherapy Committee American Academy Allergy Asthma Immunology. Twelve years of survey of fatal reactions to allergen injections and skin testing 1990-2001. J Allergy Clin Immunol 2004; 113:1129-36.
45. Lin MS, Tanner E, Lynn J, Friday GA Jr. Non fatal systemic allergic reactions induced by skin test and immunotherapy. Ann Allergy 1993; 71:557-62.
46. Hetal S, Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169-75.
47. Tinkelman DG, Cole WQ III, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995; 95:8-14.
48. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009; 103:451-59.
49. Committee on the Safety of Medicines. Desensitizing vaccines. BMJ 1989; 293:948.
50. Nettis E, Giordano D, Pannofino A, Tursi A. Safety of inhalant allergen immunotherapy with mass units-standardized extracts. Clin Exp Allergy 2002; 32:1745-9.
51. Ragusa RF, Passalacqua G, Gambardella R et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10 years experience. J Invest Allergol Clin Immunol 1997; 7:151-4.
52. Moreno C, Cuesta-Herranza J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004; 34:527-31.
53. Schiappoli M, Ridolo E, Senna G et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin Exp Allergy 2009; 39:1569-74.
54. Rank MA, Oslie CL, Krogman JL, Park MA, Li JT. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 2008; 29:400-5.
55. Canonica GW. editor World Allergy Organization position paper on sublingual immunotherapy. Allergy 2009; 64 (Suppl 91):1-59.
56. Dahl R, Stender H, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185-90.
57. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007; 18:47-57.
58. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual Immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997; 8:21-7.
59. Bousquet J, Scheinmann P, Guinnepain MT. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double-blind placebo-controlled study. Allergy 1999; 54:249-60.
60. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol (Madrid) 1990; 18:277-84.
61. Ippoliti F, De Sanctis W, Volterrani A et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216-21.
62. Vourdas D, Syrigou E, Potamianou P et al. Doubleblind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998; 53:662-72.
63. Pajno GB, Morabito L, Barberio G. Clinical and immunological effects of long-term sublingual immunotherapy in asthmatic children sensitized to mite: a double-blind study. Allergy 2000; 55:842-9.
64. Niu CK, Chen WY, Huang JL, Lue KH, Wang YJ. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006; 100:1374-83.
65. Lue KH, Lin YH, Sun HL et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408-15.
66. Stelmach I, Kaczmarek-WoŸniak J, Majak P, Oszlowiek-Chlebna M, Jerzynska A. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009; 39:401-8.
67. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167-73.
68. Pajno G, Passalacqua G, Vita D, Permiani S, Barberio G. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 2004; 59:883-7.
69. Calamita Z, Saconato H, Bronhara Pelà A, Atallah AN. Efficacy of sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy 2006; 61:1162-72.
70. Penagos M, Passalacqua G, Compalati E, Tarantini F, Canonica GW. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599-609.
71. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009; 64:1570-9.
72. Di Bona D, Plaia A, Scafidi V, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010; 126:558-66.
73. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-7.
74. Marogna M, Tomassetti D, Bernasconi A et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008; 101:206-11.
75. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003; 33:1641-7.
76. Marogna M, Spadolini I, Massolo A et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009; 102:69-75.
77. Marogna M, Colombo T, Spadolini I et al. Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. J Investig Allergol Clin Immunol 2010; 20:146-52.
78. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021-35.
79. Dunsky E, Goldstein MF, Dvorin MJ, Belecanech GA. Anaphylaxis due to sublingual immunotherapy. Allergy 2006; 61:1235.
80. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61:1236.
81. Eifan AO, Keles S, Bahceciler NN, Barman IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007; 62:567-8.
82. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63:374.
83. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009; 64:963-4.
84. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61:181-4.
85. Brozek JL, Baena Cagnani C, Canonica GW et al. Methodology for development of the allergic rhinitis and its impact on asthma guideline 2008 update. Allergy 2008; 63:38-46.
86. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126:466-76.